Insulin Therapy and Cancer in Type 2 Diabetes

Table 2

Epidemiological studies comparing glargine and human insulin with respect to the incidence of cancer.

Study [Ref]	Design	Comparator insulin	Main results
Hemkens et al., 2009 [35]	Cohort	Any human	Increased risk after adjusting for doses
Colhoun, 2009 [40]	Cohort	Any human	No effect on overall cancer; increased risk of breast cancer
Jonasson et al., 2009 [45]	Cohort	Any human	No effect on overall cancer; increased risk of breast cancer
Currie et al., 2009 [34]	Cohort	NPH	No effect
Mannucci et al., 2010 [90]	Case-control	NPH	No overall effect; increased overall risk for high doses (>0.3 U/kg*day)
Ljung et al., 2011 [91]	Cohort	Any human	No effect (new short-term cohort)
Chang et al., 2011 [92]	Cohort	NPH	No effect on overall cancer; increased risk of prostate and pancreas cancer, but not of breast cancer
Morden et al., 2011 [93]	Cohort	Any human	No effect on overall cancer; increased risk of breast (but not prostate) cancer at high doses (upper quartile)
Ruiter et al., 2012 [95]	Cohort	Any human	Reduced risk of overall cancer; dose-dependent increase in the risk of breast and prostate cancer
Suissa et al., 2011 [96]	Cohort	Any human	Increased risk of breast cancer for long-term (>5 years) use
Lind et al., 2012 [97]	Cohort	Any human	Increased risk of breast cancer, dose-dependent; nonsignificant trend for prostate cancer
Van Staa et al., 2012 [39]	Cohort	NPH	No effect
Blin et al., 2012 [94]	Cohort	Human insulin	No effect